Macrophage‐Tased Dual‐Phase T Cell Immunomodulation to Combat Transplant Rejection
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202403591 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Wenyuan Wang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. Hauptthemen laut MEDLINE: Graft Rejection, Macrophages, B7-H1 Antigen, Immunomodulation. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Natural Science Foundation of China, Natural Science Foundation of Hubei, Key Research and Development Technology Program of Zigong First People's Hospital.
Abstract (Originalsprache)
Transplant rejection remains a major challenge, driven primarily by the activation of alloreactive T cells. While enhancement of PD‐L1 checkpoint molecules has exhibited potential in inhibiting T cell activity, its efficacy is often hindered by limited specificity and inadequate efficiency. Herein, a novel dual‐phase immune modulation strategy is developed in which CTLA4‐Ig and PD‐L1 provide distinct, non‐redundant inhibitory signals during the initial activation phase and the post‐activation phase of T cells. PD‐L1 is stably expressed on macrophages (sPD‐L1 M) through lentiviral transduction, allowing them to leverage their chemotactic and antigen‐presenting functions to target and deliver PD‐L1 to transplant rejection sites. Notably, sPD‐L1 M exhibited adaptive targeting capabilities, increasing their migration to grafts in response to heightened rejection. In an allograft skin model, the combined intravenous administration of sPD‐L1 M and subcutaneous administration of CTLA4‐Ig demonstrated synergistic efficacy, significantly suppressing alloreactive T cell activation, enhancing the recruitment of regulatory T cells (Tregs), downregulating pro‐inflammatory cytokines, and prolonging allograft survival compared to either treatment alone. This study presents a promising strategy to effectively suppress T cell activity and prevent allogeneic immune responses without systemic immunosuppression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
- Hubei Province Clinical Research Center for Medical Imaging, Wuhan, 430022, China.
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China.
ORCID-Profile: Li Zhang
Förderung
- Natural Science Foundation of China
- Natural Science Foundation of Hubei
- Key Research and Development Technology Program of Zigong First People's Hospital
- Natural Science Foundation of Wuhan
- Postdoctoral Science Foundation of China and Hubei
- National Natural Science Foundation of China
Zitieren
APA
Wang, W., Gao, T., Wang, Y., Wang, R., He, M., Wang, L., Zhou, W., Ding, M., Song, Y., Ji, X., Li, X., Song, Y., Zhu, Y., Zhang, Y., Xie, Y., Chen, Y., Jin, Q., Xie, M., & Zhang, L. (2025). Macrophage‐Tased Dual‐Phase T Cell Immunomodulation to Combat Transplant Rejection. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202403591
Vancouver
Wang W, Gao T, Wang Y, Wang R, He M, Wang L, et al. Macrophage‐Tased Dual‐Phase T Cell Immunomodulation to Combat Transplant Rejection. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202403591
BibTeX
@article{Wang2025,
author = {Wang, Wenyuan and Gao, Tang and Wang, Yihui and Wang, Rui and He, Mengrong and Wang, Lufang and Zhou, Wuqi and Ding, Mengdan and Song, Yuan and Ji, Xiang and Li, Xueke and Song, Yishu and Zhu, Ye and Zhang, Yiwei and Xie, Yuji and Chen, Yan and Jin, Qiaofeng and Xie, Mingxing and Zhang, Li},
title = {Macrophage‐Tased Dual‐Phase T Cell Immunomodulation to Combat Transplant Rejection},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202403591}
}
EUVIMED